Trial Search Results
Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases
We hope to determine the maximum tolerated dose of 3 session (i.e., treatment) stereotactic radiosurgery to treat brain metastases greater than 4.2 cm3 in size. By increasing radiation dose, we will determine if there is a better outcome without greater toxicity (side effects) for patients.
Stanford is currently not accepting patients for this trial.
- Radiation: Fractionated Stereotactic Radiosurgery
- Procedure: Surgical resection of the tumor
- Age 18 years and older with pathologically-proven solid tumor malignancy and 1 to 4
brain metastases, one of which is 4.2 to 33.5 cm^3.
- Systemic therapy: Prior cytoxic systemic therapy must be completed ≥ 5 days prior to
radiosurgery. No concurrent cytoxic systemic therapy along with SRS. Cytoxic systemic
therapy to start ≥ 5 days after the completion of SRS.
- Prior surgery or SRS is allowed as long as the target metastatic lesion in this study
has not previously been treated with SRS.
- Ability to understand and the willingness to sign a written informed consent.
- Life expectancy of ≥ 12 weeks.
- Previously treated with whole brain irradiation
- Metastatic lesion in question has previously been treated with SRS.
- > 4 total brain metastases at the time of initial evaluation.
- Pediatric patients (age < 18), pregnant women, and those who are unable to give
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study